RANGE AT RHEUMATOID ARTHRITIS AGAINST THERAPY THE RITUKSIMABY
Abstract
The main aim of our research was to study the dynamics of indexes of lipid profile from patients with rheumatoid arthritis during 52 weeks. We have found that the therapy with rituximab in combination with me- totrexate brings the reduction of clinic and immunological activities, improvement of functional activism in pa- tients and reduction of atherogenic factor.
About the Authors
Vadim Ivanovich Mazurov
The North Western State Medical University of I.I.Mechnikov
Russian Federation
Russian Federation
Sofia Razmetovna Avlokhova
The North Western State Medical University of I.I.Mechnikov
Russian Federation
Russian Federation
References
1. Ревматология. Клинические рекомендации / под ред. Е. Л. Насонова. М.: ГЭОТАР-Медиа, 2011. С. 678–702.
2. Symmons D. Long term mortality outcomes in patients with rheumatoid arthritis: early presenters continue to do well / D. Symmons, M. Jones, D. Scott [et al.] // The Journal of Rheumatology. 1998. № 25(6). 1072–1073.
3. Lopes-Gongo F. Association between anticyclic citrullinated peptide antibodies and ischemic heart disease in patients with rheumatoid arthritis / F. Lopes-Gongo, D. Oliver Minario, I. De la Torre [et al.] // Arthritis & Rheu- matism. 2009. № 61(4). Р. 419−424.
4. Pincus T. What is the natural history of rheumatoid arthritis? / T. Pincus, L. Callahan // Rheumatic Disease Clinics of North America. 1993. № 19. Р. 123−126.
5. Meune C. Trends in cardiovascular mortality in patients with rheumatoid arthritis over 50 years: a system- atic review and meta-analisis of cohort studies / C. Meune, E. Touze, L. Trinqurte [et al.] // Rheumatology. 2009. № 48(10). Р. 1309–1313.
6. Nurmohamed M. Dyslipidemia, statins and rheumatoid arthritis / M. Nurmohamed, B. Dijkmans // Annals of the Rheumatic Diseases. 2009. № 68. Р. 453–455.
7. Gazi I. F. Clustering of cardiovascular risk factors in rheumatoid arthritis: the rationale for using statins / I. F. Gazi, D. T. Boumpas, D. P. Mikhailidis [et al.] // Clinical and Experimental Rheumatology. 2007. № 25. Р. 102–111.
8. Попкова Т. В. Роль нарушений в системе транспорта холестерина крови в развитии атеросклероза при ревматоидном артрите / Т. В. Попкова, Д. С. Новикова, А. А. Новиков [и др.] // Научно-практическая ревматология. 2007. № 5. С. 4–10.
9. Bisoendial R. J. Targeting cardiovascular risk in rheumatoid arthritis: a dual role for statins / R. J. Bisoen- dial, E. S. Stroes, J. J. Kastelein [et al.] // Nature Reviews Rheumatology. 2010. № 6. Р. 157–164.
10. Колесова Е. П. Сердечно-сосудистый риск у больных ревматоидным артритом / Е. П. Колесова, А. Л. Маслянский [и др.] // Бюллетень ФЦСКЭ им. В. А. Алмазова. 2012. № 4. С. 47–53.
11. Sattar N. Explaining how “high-grade” systemic inflammation accelerates vascular risk in rheumatoid ar- thritis / N. Sattar, D. McCarey, H. Capell [et al.] // Circulation. 2003. № 16 (108). Р. 2957–2963.
12. Ozbalkan Z. Новые данные о связи ревматоидного артрита и атеросклероза / Z. Ozbalkan, C. Efe, M. Cesur [et al.] // Атеросклероз и дислипидемии. 2011. № 3. С. 4−11.
13. Bosello S. TNF-alpha blockade induces a reversible but transient effect on endothelial dysfunction in pa- tients with long-standing severe rheumatoid arthritis / S. Bosello, А. Santoliquido, А. Zoli [et al.] // Clinical Rheuma- tology. 2008. № 27(7). Р. 833−839.
14. Gonzalez-Juanatey C. Short-term improvement of endothelial function in rituximabtreated rheumatoid ar- thritis patients refractory to tumor necrosis factor alpha blocker therapy/ C. Gonzalez-Juanatey, J. Llorca, T. Vazquez- Rodriguez [et al.] // Arthritis & Rheumatism. 2008. № 59(12). Р. 1821–1824.
15. Smolen J. S. EULAR recommendations for the management of rheumatoid arthritis with synthetic and bio- logical disease-modifying antirheumatic drugs / J. S. Smolen, R. Landewé, F. C. Breedveld [et al.] // Annals of the Rheumatic Diseases. 2010. Vol. 69(6). P. 964–975.
16. Kerekes G. Effects of rituximab treatment on endothelial dysfunction,carotid atherosclerosis, and lipid profi le in rheumatoid arthritis / G. Kerekes, P. Soltész, H. Dér [et al.] // Clinical Rheumatology. 2009. Vol. 28(6). P. 705–710.
17. Ajeganova S. Effect of biological therapy on levels of atheroprotective antibodies against phosphorylcho- line and apolipoproteins in rheumatoid arthritis – a one year study / S. Ajeganova, R. Fiskesund, U. de Faire [et al.] // Clinical and Experimental Rheumatology. 2011. Vol. 29(6). P. 942–950.
18. Буеверова Е. Л. Атерогенная дислипидемия и печень / Е. Л. Буеверова, О. М. Драпкина, В. Т. Иваш- кин // Российские медицинские вести. 2008. Том 12 (№ 1). С. 17−23.
19. Национальные клинические рекомендации: сборник / под ред. Р. Г. Оганова. 2-е изд. М.: Силицея- Полиграф, 2009. С. 20–106.
Review
For citations:
Mazurov V.I., Avlokhova S.R. RANGE AT RHEUMATOID ARTHRITIS AGAINST THERAPY THE RITUKSIMABY. Newsletter of North-Caucasus Federal University. 2013;(5):52-56. (In Russ.)
Views:
86
Email this article 